{Reference Type}: Journal Article
{Title}: Pathophysiological role and potential drug target of NLRP3 inflammasome in the metabolic disorders.
{Author}: Hu H;Wang S;Chen C;
{Journal}: Cell Signal
{Volume}: 122
{Issue}: 0
{Year}: 2024 Oct 25
{Factor}: 4.85
{DOI}: 10.1016/j.cellsig.2024.111320
{Abstract}: NLRP3 plays a role in the development of autoinflammatory diseases. NLRP3, ASC, and Caspases 1 or 8 make up the NLRP3 inflammasome, which is an important part of innate immune system. The NLRP3 inflammasome-mediated inflammatory cytokines may also participate in metabolic disorders, such as diabetes, hyperlipidemia, atherosclerosis, non-alcoholic fatty liver disease, and gout. Hence, an overview of the NLRP3 regulation in these metabolic diseases and the potential drugs targeting NLRP3 is the focus of this review.